TABLE 3.
Adverse events of each group
| AE categorya | Frequency by group (no. of patients [%])b |
P | |||
|---|---|---|---|---|---|
| LR-BAC (n = 109) | LR-BAT (n = 109) | HR-BAC (n = 106) | HR-BAT (n = 107) | ||
| Total no. of AEs | 10 | 6 | 30 | 11 | |
| No. of patients with AEs | 8 (7.3) | 5 (4.6) | 13 (12.3) | 7 (6.5) | 0.1840 |
| Liver system | 0 | 0 | 2 (1.9) | 0 | |
| CNS disorders | 6 (5.5) | 2 (1.8) | 10 (9.4) | 4 (3.7) | 0.0733 |
| Headache | 0 | 0 | 3 (2.8) | 1 (0.9) | |
| Dizziness | 3 (2.8) | 2 (1.8) | 6 (5.7) | 3 (2.8) | 0.4220 |
| Dysgeusia | 3 (2.8) | 0 | 4 (3.8) | 0 | |
| Skin rash | 0 | 2 (1.8) | 1 (0.9) | 3 (2.8) | |
| Gastrointestinal disorders | 3 (2.8) | 1 (0.9) | 7 (6.6) | 1 (0.9) | 0.0370 |
| Vomiting | 1 (0.9) | 0 | 2 (1.9) | 0 | |
| Abdominal pain | 0 | 0 | 2 (1.9) | 0 | |
| Bloating | 2 (1.8) | 1 (0.9) | 3 (2.8) | 0 | |
| diarrhea | 0 | 0 | 0 | 1 (0.9) | |
| Other | 1 (0.9) | 1 (0.9) | 4 (3.8) | 1 (0.9) | |
a
AE, adverse event.
b
Total AE values are the numbers of events. LR-BAC group, rabeprazole at 10 mg b.i.d. plus bismuth, amoxicillin, and clarithromycin; LR-BAT group, rabeprazole at 10 mg b.i.d. plus bismuth, amoxicillin, and tetracycline; HR-BAC group, rabeprazole at 20 mg b.i.d. plus bismuth, amoxicillin, and clarithromycin; HR-BAT group, rabeprazole at 10 mg b.i.d. plus bismuth, amoxicillin, and tetracycline.